# Daily report — trading day 2026-10-16 (Friday)

*Written by the run that started 19:18:47Z (15:18 ET), invoked with **prompt v16**. Figures are broker figures priced at 19:19Z, not the close. This run started before the 15:20–15:52 ET decision window, so it placed no sleeve orders. The 15:25 ET decision-window run amends Section 1 with its decisions.*

**Today in one line:** a broad semis and tech sell-off. QQQ is −2.60% (709.06), MU −5.2%, and Ryan's MU 1220C is down to $708. The sleeves lost about 5% with it. Drawdown on sleeve value is −2.03%, nowhere near the −20% notice level.

## 1. Sleeves
**SWING_Q:** QLD 1.147609 sh = **$100.43** (−$5.85, −5.5% vs cost; QLD −5.25% today). Cash is **$83.39**, below the 5% reserve ($62.49 on total value $1,249.73), so **deployable cash is $20.90**. The decision-window run can fund almost nothing unless a sell frees cash.

**SWING_M (6 names, all `placed_agent: agentic`):**

| Name | Value | P/L vs cost | Today |
|---|---|---|---|
| AMD | $85.50 | −$13.81 (−13.9%) | −5.59% |
| MU | $84.54 | −$14.77 (−14.9%) | −5.22% |
| INTC | $69.91 | −$23.82 (−25.4%) | −5.95% |
| WDC | $68.92 | −$24.81 (−26.5%) | −5.75% |
| LITE | $47.06 | −$8.61 (−15.5%) | −4.54% |
| DELL | $1.91 | −$0.20 (−9.3%) | −2.97% |

Not held: MRNA (sold 10-14), VIAV, MRVL, ILMN. Orders today: none (broker, 19:19Z). The sleeves carry no stops; the rules exit on a close above the 5-day SMA, IBS > 0.8 or the 5-session IBS limit.

**Decision window (run 15:25:22 ET, decide() at 19:25:30Z, TV $1,248.83):** every target ON. QLD kept (RSI2 0.7 + IBS 0.172; target $830.47, no mid-month resize). MU, LITE, DELL, WDC, AMD, INTC kept. No sells. MRNA, VIAV, MRVL, ILMN were ON ($35.59 target each) but not held; deployable cash was $20.95, so the run **bought MRNA $20.95 = 0.098275 sh @ $213.18** (first in pick order, IBS 0.137). VIAV, MRVL and ILMN are unfunded. Sleeve drawdown −1.97% vs HWM.

## 2. Legacy run-off
Done. No `sleeve: "swing"` positions remain.

## 3. Options
No agentic options. Ryan's **MU 2026-12-18 1220C ×1** (`placed_agent: "user"`, $1,250 cost) is marked at **$708 (−$542, −43%)**, with MU at $882.64. It is his position: the agent records it and never closes it. He has set no exit levels for it.

## 4. Growth paper
Marked at 19:19Z: **$293.19 on $328.90 cost (−10.86%)**. PLTR −2.02%, NVDA −9.53%, NTRA −6.44%, CRWD −16.95%, NET −19.34%. NET is 5.7 points above its −25% exit (paper level $272.30). Exits are checked on Monday.

## 5. Account vs QQQ
- **Total value: $1,249.73.**
- **Sleeve value: $3,531.73.** This is the drawdown basis. It leaves out Ryan's MU option P/L: −$542 unrealized and −$1,740 realized since 10-13.
- Since 2026-09-30, on sleeve value: **+6.50%**. QQQ: **−4.14%** (739.71 → 709.06). Today QQQ −2.60%.
- **Drawdown from the $3,604.85 high-water mark: −2.03%.**

## 6. Week (provisional; broker, read 19:19Z)
Realized this week: **−$1,736.44 over 3 closes**. Ryan's MU 1160C made −$1,740 of that; the agent's closes made +$3.56 (MRNA and a 10-12 close). Sleeve orders this week came only from the 10-14 decision window (MRNA sell plus the legacy close-out). The 10-15 window placed nothing (deployable cash below one dollar); the 10-16 window bought MRNA $20.95 with the only deployable cash. The Friday review is in the journal; the decision-window run amends it.

## 7. Next week
- Turn-of-month leg: off until the last trading day of October (Oct 30).
- No legacy deadline left.
- Monday: weekly scorecard and growth-paper research and exits (watch NET and CRWD against −25%).
- Capital: the sleeves stay mostly unfunded (about $458 of a ~$1,190 base target) while Ryan's MU option holds the cash. Nothing is sold to fund them.
